Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
2019 · Annals of Oncology · 112 citations
https://doi.org/10.1093/annonc/mdz061